South Dakota Investment Council Intercept Pharmaceuticals, Inc. Transaction History

South Dakota Investment Council

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$15.46 - $24.5 $106,519 - $168,805	-6,890 Closed	0 $0
Q4 2019 Feb 11, 2020	SELL	$57.36 - $124.1 $138,237 - $299,081	-2,410 Reduced 25.91%	6,890 $854,000
Q2 2019 Aug 13, 2019	SELL	$77.77 - $120.68 $746,592 - $1.16 Million	-9,600 Reduced 50.79%	9,300 $740,000
Q4 2018 Feb 06, 2019	SELL	$85.79 - $126.46 $609,109 - $897,866	-7,100 Reduced 27.31%	18,900 $1.91 Million
Q3 2018 Nov 14, 2018	SELL	$88.49 - $127.55 $230,074 - $331,630	-2,600 Reduced 9.09%	26,000 $3.29 Million
Q2 2018 Aug 13, 2018	SELL	$60.0 - $85.67 $1.02 Million - $1.46 Million	-17,000 Reduced 37.28%	28,600 $2.4 Million
Q4 2017 Feb 09, 2018	BUY	$58.2 - $72.76 $174,600 - $218,280	3,000 Added 7.04%	45,600 $2.66 Million
Q3 2017 Nov 09, 2017	BUY	$57.01 - $118.75 $2.43 Million - $5.06 Million	42,600	42,600 $2.47 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of South Dakota Investment Council, based on Form 13F filings with the SEC.

Stay updated on South Dakota Investment Council with notifications on news.